Press Release and Management Discussion & Analysis - Q2FY26 Results
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Midcap 150 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Glenmark Pharmaceuticals has filed its Q2 FY26 earnings press release along with the Management Discussion & Analysis on the NSE portal. The document typically covers the company's quarterly financial performance, revenue and profit figures, segment-wise breakdown across formulations, API and specialty business, operating margin trends, R&D spend, capex, and debt position. The MD&A also provides management commentary on business outlook, key growth drivers, regulatory updates, and strategic priorities for the remaining part of the fiscal year. Investors should review the detailed numbers and guidance in the attached press release for specific performance metrics.
This is an informational filing accompanying the Q2 results and does not by itself trigger a stock movement; the actual numbers and management guidance within the release and MD&A will shape near-term investor sentiment on the stock.